Latvija - latvijski - Zāļu valsts aģentūra

dr. falk pharma gmbh, germany - mesalazīns - ilgstošās darbības granulas - 3 g

Europska Unija - latvijski - EMA (European Medicines Agency)

bristol-myers squibb pharma eeig - ozanimod hidrohlorīds - multiple sclerosis, relapsing-remitting; colitis, ulcerative - imūnsupresanti - multiple sclerosiszeposia is indicated for the treatment of adult patients with relapsing remitting multiple sclerosis (rrms) with active disease as defined by clinical or imaging features. ulcerative colitiszeposia is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis (uc) who have had an inadequate response, lost response, or were intolerant to either conventional therapy or a biologic agent.

Latvija - latvijski - Zāļu valsts aģentūra

tillotts pharma ab, sweden - mesalazīns - supozitorijs - 1 g

Latvija - latvijski - Zāļu valsts aģentūra

actavis group ptc ehf., iceland - doksorubicīna hidrohlorīds - koncentrāts infūziju šķīduma pagatavošanai - 2 mg/ml

Europska Unija - latvijski - EMA (European Medicines Agency)

pfizer europe ma eeig - tofacitinibs - artrīts, reimatoīds - imūnsupresanti - rheumatoid arthritistofacitinib in combination with methotrexate (mtx) is indicated for the treatment of moderate to severe active rheumatoid arthritis (ra) in adult patients who have responded inadequately to, or who are intolerant to one or more disease-modifying antirheumatic drugs (dmards) (see section 5. tofacitinib can be given as monotherapy in case of intolerance to mtx or when treatment with mtx is inappropriate (see sections 4. 4 un 4. psoriatic arthritistofacitinib in combination with mtx is indicated for the treatment of active psoriatic arthritis (psa) in adult patients who have had an inadequate response or who have been intolerant to a prior disease modifying antirheumatic drug (dmard) therapy (see section 5. ulcerative colitistofacitinib is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis (uc) who have had an inadequate response, lost response, or were intolerant to either conventional therapy or a biologic agent (see section 5. tofacitinib is indicated for the treatment of active polyarticular juvenile idiopathic arthritis (rheumatoid factor positive [rf+] or negative [rf-] polyarthritis and extended oligoarthritis), and juvenile psoriatic arthritis (psa) in patients 2 years of age and older, who have responded inadequately to previous therapy with disease modifying antirheumatic drugs (dmards). tofacitinib can be given in combination with methotrexate (mtx) or as monotherapy in case of intolerance to mtx or where continued treatment with mtx is inappropriate. ankylosing spondylitistofacitinib is indicated for the treatment of adult patients with active ankylosing spondylitis (as) who have responded inadequately to conventional therapy.

Latvija - latvijski - Zāļu valsts aģentūra

berlin-chemie ag (menarini group), germany - sulfamethoxazolum, trimethoprimum - tablete - 800 mg/160 mg

Latvija - latvijski - Zāļu valsts aģentūra

vitabalans oy, finland - thiamini hydrochloridum, cyanocobalaminum, pyridoxini hydrochloridum - apvalkotā tablete

Europska Unija - latvijski - EMA (European Medicines Agency)

biosimilar collaborations ireland limited - adalimumab - hidradenitis suppurativa; psoriasis; uveitis; arthritis, rheumatoid; spondylitis, ankylosing; crohn disease; colitis, ulcerative; arthritis, psoriatic - immunosuppressants, audzēja nekrozes faktora alfa (tnf-α) inhibitorus

Latvija - latvijski - Zāļu valsts aģentūra

rokitan gmbh, austria - trimethoprimum, sulfametrolum - apvalkotā tablete - 800 mg/160 mg

Latvija - latvijski - Zāļu valsts aģentūra

accord healthcare b.v., netherlands - metotreksāts - koncentrāts infūziju šķīduma pagatavošanai - 100 mg/ml